Sarina Tanimoto - CHIEF MEDICAL OFFICER, 10%+ Owner at ARS Pharmaceuticals, Inc.

Issuer-level insider activity

Role: CHIEF MEDICAL OFFICER, 10%+ Owner
Issuer ticker: SPRY on Nasdaq
Entity type: Individual
Source filing history: Open source filing history

No buys or sells have been reported by Sarina Tanimoto since 05 Sep 2025

Reported holdings for Sarina Tanimoto in ARS Pharmaceuticals, Inc.

Form 4 holding CHIEF MEDICAL OFFICER, 10%+ Owner

ARS Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 8,859,200
Estimated value: $162,566,320
Report date: 19 Aug 2025
Price: $18.35
Ownership: By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Form 4 holding CHIEF MEDICAL OFFICER, 10%+ Owner

ARS Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 1,246,494
Estimated value: $22,873,164
Report date: 19 Aug 2025
Price: $18.35
Ownership: By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Form 4 holding CHIEF MEDICAL OFFICER, 10%+ Owner

ARS Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 1,247,447
Estimated value: $17,578,274
Report date: 20 Aug 2025
Price: $14.09
Ownership: By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020

Form 4 holding CHIEF MEDICAL OFFICER, 10%+ Owner

ARS Pharmaceuticals, Inc.

Security class: Stock Option (right to buy)
Shares / value: 875,000
Estimated value
Report date: 02 Jan 2026
Price
Ownership: By Spouse
Underlying class: Common Stock
Underlying amount

Form 4 holding CHIEF MEDICAL OFFICER, 10%+ Owner

ARS Pharmaceuticals, Inc.

Security class: Stock option (right to buy)
Shares / value: 240,000
Estimated value
Report date: 02 Jan 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Transaction history for Sarina Tanimoto in ARS Pharmaceuticals, Inc.

Sym	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares after	Date	Ownership

^* marks a reported price that did not pass the local price check.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .